Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
11
×
national top stories
11
×
boston blog main
new york top stories
boston top stories
new york blog main
clinical trials
fda
san francisco blog main
san francisco top stories
san diego blog main
san diego top stories
biotech
national
boston
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
drugs
europe top stories
indiana blog main
indiana top stories
new york
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
akcea therapeutics
allergan
alnylam pharmaceuticals
cancer
europe blog main
hereditary transthyretin amyloidosis
inotersen
What
drug
11
×
medicine
11
×
fda
approved
new
cancer
alnylam
announced
disease
gain
making
medicines
oks
patients
post
rnai
specifically
weight
aces
afternoon
alkermes
alnylam’s
alzheimer's
antipsychotic
approves
atrophy
backs
bad
benefits
bets
big
brain
brexanolone
case
caveats
cells
ceo
cholesterol
click
commonly
Language
unset
Current search:
medicine
×
drug
×
" national top stories "
×
" national blog main "
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
4 years ago
Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?
@xconomy.com
5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Sanofi Backs Click Therapeutics as Digital Medicines Gain Momentum